Drugs最新文献 - Book学术

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-17 DOI: 10.1007/s40265-025-02165-1

Arnold Lee

引用次数: 0

PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis. PI3K抑制剂作为COPD合并动脉粥样硬化的潜在治疗药物

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1007/s40265-025-02179-9

Mario Cazzola, Clive Page, Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera

{"title":"PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis.","authors":"Mario Cazzola, Clive Page, Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera","doi":"10.1007/s40265-025-02179-9","DOIUrl":"10.1007/s40265-025-02179-9","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) share a complex and multifactorial relationship characterized by overlapping risk factors, systemic inflammation, and intertwined pathophysiological mechanisms, with atherosclerosis emerging as a central inflammatory process connecting COPD and CVD, driven by systemic inflammation, oxidative stress, and endothelial dysfunction. While systemic inflammation is recognized as a critical link between these conditions, the precise pathways through which inflammation arises remain under investigation. There is therefore a need for therapeutic strategies to mitigate cardiovascular risks in patients with COPD. Among the pathways contributing to this interplay, the phosphoinositide 3-kinase (PI3K) signaling pathway has gained significant attention. Dysregulated PI3K signaling contributes to inflammation, oxidative stress, and endothelial dysfunction, which are key drivers of both COPD and CVD. Consequently, PI3K inhibitors have emerged as a promising therapeutic approach to mitigate inflammation and oxidative damage, offering a targeted strategy to address the shared pathological mechanisms underlying these diseases. A comprehensive understanding of the role of PI3K signaling and its inhibitors could facilitate the development of novel interventions to reduce cardiovascular risk in patients with COPD.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"741-753"},"PeriodicalIF":13.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Potential of Centhaquine Citrate, a Selective Alpha-2B Adrenoceptor Agonist, in the Management of Circulatory Shock. 选择性α - 2b肾上腺素能受体激动剂柠檬酸氯喹治疗循环休克的潜力。

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-20 DOI: 10.1007/s40265-025-02176-y

Matthieu Legrand, Amaresh Ranjan, Shruthi Rammohan, Daniel De Backer, Marlies Ostermann, Anil Gulati, Jean-Louis Vincent, Ashish K Khanna

引用次数: 0

Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study. 胰高血糖素样肽-1受体激动剂与酒精使用障碍和糖尿病患者进展为肝硬化和酒精相关入院的关系：一项回顾性队列研究

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-13 DOI: 10.1007/s40265-025-02177-x

Feras Al-Moussally, Saud Khan, Vinay Katukuri, Mustafa Kinaan, Ishak A Mansi

{"title":"Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.","authors":"Feras Al-Moussally, Saud Khan, Vinay Katukuri, Mustafa Kinaan, Ishak A Mansi","doi":"10.1007/s40265-025-02177-x","DOIUrl":"10.1007/s40265-025-02177-x","url":null,"abstract":"Aim: In recent years, use of glucagon-like peptide-1 receptor agonists (GLP-1RA) has exponentially increased due to their beneficial effects on weight loss and cardiovascular outcomes. Lately, some animal studies and observational data suggested that GLP-1RA may be useful in the treatment of alcohol use disorder (AUD). We aim to compare the risk of progression to liver cirrhosis and alcohol-related hospital admission after initiation of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4i), as the active comparator, in patients with type 2 diabetes mellitus and AUD.Methods: We conducted a retrospective propensity score-matched cohort study, utilizing new-user and active comparator design. The study used data from the Veterans Health Administration during fiscal years 2006 to 2021 encompassing adults with AUD who initiated either GLP-1RA or DPP4i prescriptions. Our two co-primary outcomes were progression to cirrhosis (compensated and decompensated cirrhosis) and alcohol-related hospital admission.Results: The eligible cohort included 9965 GLP-1RA users and 19,688 DPP4i users. After propensity score matching, 7302 pairs were matched on 79 characteristics without residual imbalances. In the propensity score-matched cohort, progression to cirrhosis occurred in 6.6% of GLP-1RA users and 6.0% DPP4i users; odds ratio (OR): 1.1, 95% confidence interval (95% CI): 0.97-1.26. Alcohol-related hospital admission occurred in 1.4% of GLP-1RA users and in 1.7% of DPP4i users (OR: 0.85; 95% CI: 0.65-1.11).Conclusions: Use of GLP-1RA in patients with AUD was not associated with beneficial effect on progression to cirrhosis or alcohol-related hospital admission.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"813-825"},"PeriodicalIF":13.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differentiating IL-23 Inhibitors in Crohn's Disease. 克罗恩病中IL-23抑制剂的鉴别

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1007/s40265-025-02183-z

Olga Maria Nardone, Sudheer K Vuyyuru, Yuhong Yuan, Jurij Hanzel, Vipul Jairath

{"title":"Differentiating IL-23 Inhibitors in Crohn's Disease.","authors":"Olga Maria Nardone, Sudheer K Vuyyuru, Yuhong Yuan, Jurij Hanzel, Vipul Jairath","doi":"10.1007/s40265-025-02183-z","DOIUrl":"10.1007/s40265-025-02183-z","url":null,"abstract":"Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory bowel disease (IBD). Therapies targeting the p19 subunit of IL-23 have recently expanded the therapeutic options for IBD demonstrating efficacy and safety for the treatment of moderate to severe Crohn's disease (CD). Thus, in this review, we provide an overview of agents targeting the IL-23 pathway in CD, highlighting similarities and differences of specific IL-23 inhibitors. Furthermore, we summarize key phase 3 trials and head-to-head trials, focusing on design features and interpretation. Finally, we discuss the positioning of selective IL-23 agents for CD treatment along with areas of unmet clinical needs. However, real-world data will offer additional comparative effectiveness information, data for disease subtypes, and insights into the long-term outcomes of IL-23 inhibition. Looking ahead, ongoing phase 3 studies testing p19-specific selective IL-23 inhibitors are expected to expand the therapeutic options for patients with complex phenotypes, including those with extraintestinal manifestations (EIMs), fistulas, and strictures. Advances in molecular and cellular characterization, including the development of predictive molecular biomarkers, may help guide clinical decision-making, enabling more personalized treatment approaches. Precision medicine studies may further enhance our understanding of the molecular biology of IL-23, shedding light on how these agents work in complex CD and clarify their potential complementary or synergistic effects with other therapies.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"725-740"},"PeriodicalIF":13.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acoramidis: First Approval. Acoramidis：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-04 DOI: 10.1007/s40265-025-02159-z

Arnold Lee

引用次数: 0

Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions. 降脂药物的肾脏安全性评估：在旧的确定性和新的问题之间。

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-03-19 DOI: 10.1007/s40265-025-02158-0

Daniele Tramontano, Simone Bini, Carlo Maiorca, Alessia Di Costanzo, Martina Carosi, Jacopo Castellese, Ina Arizaj, Daniela Commodari, Stella Covino, Giorgia Sansone, Ilenia Minicocci, Marcello Arca, Laura D'Erasmo

{"title":"Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions.","authors":"Daniele Tramontano, Simone Bini, Carlo Maiorca, Alessia Di Costanzo, Martina Carosi, Jacopo Castellese, Ina Arizaj, Daniela Commodari, Stella Covino, Giorgia Sansone, Ilenia Minicocci, Marcello Arca, Laura D'Erasmo","doi":"10.1007/s40265-025-02158-0","DOIUrl":"10.1007/s40265-025-02158-0","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Quantitative and qualitative changes in plasma lipoprotein profiles are frequently associated with CKD and represent a significant risk factor for CVD in patients with CKD. Guidelines from the European Society of Cardiology and the European Atherosclerosis Society classify CKD as a condition with high or very high cardiovascular risk and set specific low-density lipoprotein cholesterol targets. Conventional lipid-lowering therapies (LLTs), such as statins, ezetimibe, and fibrates, can control CKD-associated dyslipidemia and, to some extent, prevent major atherosclerotic events in patients with CKD, but their use in clinical practice presents challenges because of the potential renal safety concerns. In recent years, novel therapies with the ability to lower both low-density lipoprotein cholesterol and triglycerides have been introduced to the market (e.g., proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, lomitapide, volanesorsen) to improve our ability to control lipid abnormalities. However, their impact on kidney functionality has not been fully elucidated. The aim of this review was to examine the renal safety profiles of various LLTs, with special reference to novel medications, and to highlight important considerations and guidance for the use of these medications in overt CKD or in patients with some degree of renal function impairment. We underscore the lack of a comprehensive understanding of kidney safety, particularly for novel LLT therapies, and strongly emphasize the importance of future dedicated research to fully assess the safety and efficacy of these agents in patients with kidney abnormalities.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"755-775"},"PeriodicalIF":13.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Garadacimab: First Approval. Garadacimab：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-22 DOI: 10.1007/s40265-025-02180-2

Simon Fung

引用次数: 0

Correction: Current and Emerging Therapies for Lysosomal Storage Disorders. 修正：溶酶体贮积症目前和新兴的治疗方法。

IF 13 1区医学

Drugs Pub Date : 2025-06-01 Epub Date: 2025-04-12 DOI: 10.1007/s40265-025-02175-z

Diego Agustín Abelleyra Lastoria, Sophie Keynes, Derralynn Hughes

引用次数: 0

Suzetrigine: First Approval. Suzetrigine：第一次批准。